phrykt

Viking Therapeutics, Inc. (VKTX): who owns it and who trades it

As of Nov 16, 2026, VKTX insiders reported 16 open-market sales worth $18.3M and 1 purchase worth $150K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Brian Lian (CEO), with $12.6M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Viking Therapeutics

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns VKTX

434 funds and institutions reported VKTX shares worth $3.1B at the end of Q2 2026, about 70% of the company. The largest holder is FMR LLC (Fidelity) with 5.5%.

Funds and institutions (13F) 70%Everyone else 30%

10 largest owners, by share of the company

FMR LLC (Fidelity)5.5%
BlackRock, Inc.5.3%
State Street Corp4.8%
Vanguard Capital Management LLC4.4%
California State Teachers Retirement System4.3%
Vanguard Portfolio Management LLC3.9%
Two Sigma Investments, LP3.4%
Morgan Stanley3.0%
Ameriprise Financial Inc1.9%
Geode Capital Management, LLC1.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)6.34M5.46%$247M+5%
BlackRock, Inc.6.19M5.33%$241M-10%
State Street Corp5.61M4.83%$219M+28%
Vanguard Capital Management LLC5.05M4.35%$197M+1%
California State Teachers Retirement System4.99M4.30%$128M+3909%
Vanguard Portfolio Management LLC4.48M3.86%$175M+0%
Two Sigma Investments, LP3.94M3.39%$154M-11%
Morgan Stanley3.49M3.00%$136M+16%
Ameriprise Financial Inc2.16M1.86%$84.1M+28%
Geode Capital Management, LLC2.10M1.81%$81.9M+1%
American Century Companies Inc1.82M1.56%$70.8M-13%
D. E. Shaw & Co., Inc.1.61M1.38%$62.6M-4%
BNP Paribas Financial Markets981,7000.85%$38.3M+82%
Citadel Advisors LLC951,5150.82%$37.1M-25%
Goldman Sachs Group Inc942,8410.81%$36.8M-2%
UBS Group AG936,0550.81%$36.5M-31%
JPMorgan Chase & Co915,1850.79%$36.4M–
Jane Street Group, LLC899,5580.77%$35.1M+20%
Susquehanna International Group, LLP816,3670.70%$31.8M+16%
Raymond James Financial Inc794,6600.68%$31M-62%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, VKTX insiders reported $150K of open-market purchases and $18.3M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$150K
1 trades, 1 people
Sales, 12 months
$18.3M
16 trades, 4 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jul 29, 2026
Filed Jul 29, 2026

Purchases and sales by month

$12.1M$12.1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 29, 2026Brian LianCEOSale148,517$33.32$4.9MForm 4
Jul 29, 2026Greg ZanteCFOSale21,217$33.47$710KForm 4
Jul 29, 2026Marianna ManciniChief Operating OfficerSale18,217$33.47$610KForm 4
Mar 10, 2026Neil William AubuchonChief Commercial OfficerPurchase4,475$33.50$150KForm 4
Jan 5, 2026Greg ZanteCFOSale31,961$32.30$1MForm 4
Jan 5, 2026Greg ZanteCFOSale13,900$33.38$464KForm 4
Jan 5, 2026Greg ZanteCFOSale10,300$34.24$353KForm 4
Jan 5, 2026Greg ZanteCFOSale1,500$32.09$48.1KForm 4
Jan 5, 2026Marianna ManciniChief Operating OfficerSale31,961$32.29$1MForm 4
Jan 5, 2026Marianna ManciniChief Operating OfficerSale13,600$33.37$454KForm 4
Jan 5, 2026Marianna ManciniChief Operating OfficerSale10,500$34.22$359KForm 4
Jan 5, 2026Marianna ManciniChief Operating OfficerSale1,600$35.07$56.1KForm 4
Jan 5, 2026Brian LianCEOSale6,400$35.07$224KForm 4
Jan 5, 2026Brian LianCEOSale53,279$33.38$1.8MForm 4
Jan 5, 2026Brian LianCEOSale41,276$34.22$1.4MForm 4
Jan 5, 2026Brian LianCEOSale132,454$32.29$4.3MForm 4
Jan 2, 2026Matthew W FoehrDirectorSale16,000$35.11$562KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Brian LianPresident & CEO, Director–$12.6MJul 29, 2026
Greg ZanteChief Financial Officer–$2.6MJul 29, 2026
Marianna ManciniChief Operating Officer–$2.5MJul 29, 2026
Matthew W FoehrDirector–$562KJan 2, 2026
Neil William AubuchonChief Commercial Officer$150K–Mar 10, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

VKTX short interest

High short interest. 18.9% of VKTX shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 8%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 24.16M VKTX shares were sold short, 18.9% of the shares outstanding, down 5.4% from the report before. At the average daily volume of 4.50M shares, buying them all back would take about 5.4 trading days (days to cover).

Shares short, % of all shares

18.9%May 15Oct 3022.7%

Days to cover

5.4May 15Oct 3015.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202624.16M18.95%-5%4.50M5.4
Oct 15, 202625.54M20.03%-1%5.83M4.4
Sep 30, 202625.92M22.22%+15%12.01M2.2
Sep 15, 202622.58M19.36%+2%1.83M12.3
Aug 31, 202622.19M19.02%-0%1.79M12.4
Aug 14, 202622.29M19.10%-1%1.68M13.3
Jul 31, 202622.54M19.32%-3%2.15M10.5
Jul 15, 202623.16M19.85%-1%2.35M9.8
Jun 30, 202623.51M20.25%+1%3.53M6.7
Jun 15, 202623.32M20.08%+4%2.00M11.6
May 29, 202622.37M19.27%+0%1.91M11.7
May 15, 202622.28M19.19%-2%1.99M11.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Viking Therapeutics company events

Viking Therapeutics filed 7 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 28, 2026.

  1. Oct 28, 2026ResultsReleased financial results. Filing
  2. Sep 28, 2026AgreementViking Therapeutics, Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein, to issue and sell 7,857,143 shares of the Company’s common stock, par value $0.00001 per share, at a public… Filing
  3. Sep 22, 2026AnnouncementViking Therapeutics, Inc. issued a press release announcing top-line results from its maintenance study of GLP-1/GIP agonist VK2735. Filing
  4. Jul 29, 2026ResultsReleased financial results. Filing
  5. May 26, 2026VoteReported shareholder vote results. Filing
  6. Apr 29, 2026ResultsReleased financial results. Filing
  7. Feb 11, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Viking Therapeutics financials

Famous investors that hold VKTX

5 of the 50 well-known investors we track reported holding VKTX in their latest 13F filing. The largest position is Ken Griffin's, worth $60.6M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.86M$60.6M0.0%+95%
Israel Englander · Millennium ManagementQ3 2026362,041$11.8M0.0%-27%
Steve Cohen · Point72 Asset ManagementQ3 2026155,216$5.1M0.0%-67%
Paul Tudor Jones · Tudor Investment CorpQ3 2026112,842$3.7M0.0%-43%
Ray Dalio · Bridgewater AssociatesQ3 202683,172$2.7M0.0%-5%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named VKTX in the last 120 days.

FiledHolderFormStake
Nov 5, 2026FMR LLC13G/A7.7%
Nov 5, 2026FMR LLC13G/A7.7%

Questions about Viking Therapeutics, Inc. (VKTX) stock

Who owns the most VKTX stock?

The largest reported owner of Viking Therapeutics, Inc. (VKTX) is FMR LLC (Fidelity), with 5.5% of the company. In total, 434 funds and institutions reported holding VKTX at the end of Q2 2026, together about 70% of the shares. See the largest owners.

Are VKTX insiders buying or selling?

In the last 12 months, VKTX insiders reported 1 open-market purchase worth $150K and 16 sales worth $18.3M. The latest trade was on Jul 29, 2026. See every trade.

What is the short interest in VKTX?

As of Oct 30, 2026, 24.16M VKTX shares were sold short, 18.9% of the shares outstanding, down 5.4% from the report before. At the average daily volume of 4.50M shares, buying them all back would take about 5.4 trading days (days to cover). See the history.

Which famous investors hold VKTX?

5 of the 50 well-known investors we track reported VKTX in their latest 13F filing, including Ken Griffin, Israel Englander, Steve Cohen. The largest position is worth $60.6M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.